It is estimated that Alopecia Areata affects approximately 100,000 people within the UK population. There is currently no cure for the condition and no generally accepted proven therapy. Furthermore, available treatments often come with side effects and are not very effective at re-growing hair.

Dithranol has been used for many years as a treatment for psoriasis and research suggests it may also be an effective treatment for Alopecia Areata. However its use as an Alopecia treatment has been hindered by the localised side effects the drug produces; users have sometimes complained of scalp irritation, staining of the skin and clothes, and an unpleasant odour.

This study aims to test the safety, efficacy & dose response characterisation of a new form of Dithranol/ProSilic (STSO1) which uses a technology that promotes slower release over a longer period, which may reduce the likelihood of these side effects. STSO1 will be administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.

Key Study Information:

  • Treatment Area:

    Alopecia Areata

  • Trial Site Locations:
    Queen Anne Street Medical Centre, London
  • Study Type:


  • Study Aim:

    To assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.

  • Recruitment Target:

    100 patients with mild to moderate Alopecia

  • Details of practice revenue available on request.
Join this study Right Arrow

Speak to our study support specialist for more information on this study.

10 minutes to participate in this study

  • 1
  • 2
  • 3
  • 4

Step One

Practice - Select a study

uMed supports multiple studies sponsored by commercial and academic institutions.

Your practice can choose a study via our website or dedicated web application.

Step Two

Practice - Review & Approve Eligible Patients

uMed runs a study specific search to identify potential participants.

uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.


Step Three

uMed - Patient Contact

Once approved, we manage patient contact on your behalf via SMS, email and/or letter.

We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.

For most studies, between 10-30% of patients engage with our outreach.


Step Four

Patient - Consents to Join Study

Congratulations! You've empowered your patients to participate in vital clinical research that is most relevant for them.

Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.


Not yet registered with uMed? Join over 400 GP Practices across the UK within the uMed Research Network and take part in the ALOPECIA study. Join the uMed Research Network.

More about ALOPECIA

Participant eligibility criteria

  • Participants must be aged 18 years or older.
  • Participants must have a confirmed diagnosis of mild to moderate patchy Alopecia Areata.
  • Participants must have no more than 50% loss of scalp hair (≤ SALT50), and no less than 10% (≥ SALT10).
  • Active Alopecia Areata must have been present for at least 6 months.

Register your interest in this study


Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.

    Study name

    Practice name

    Your name

    Your role


    Phone number